With co-delivery of PTX and IL-2 to the tumor region, the low-dosage of PTX release triggered the calreticulin (CRT) exposure on tumor cells and further induced the infiltration of CD8+ T cell into tumor tissue. The gene discussed is IL2; the disease is neoplasm.